[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell; 2009 Jul 23;138(2):286-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
  • Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained by a subset of self-renewing leukemia stem cells (LSC).
  • We found that CD47 was more highly expressed on AML LSC than their normal counterparts, and that increased CD47 expression predicted worse overall survival in three independent cohorts of adult AML patients.
  • [MeSH-major] Antigens, CD47 / immunology. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Phagocytosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Feb 15;174(4):2004-11 [15699129.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] JAMA. 2005 Sep 21;294(11):1359-66 [16174694.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2548-56 [16291597.001]
  • [Cites] Nat Rev Immunol. 2006 Jun;6(6):457-64 [16691243.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8550-9 [17142753.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):239-45 [17291742.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5062-6 [17360380.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1189-94 [17390064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13 [17576927.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2659-66 [17609428.001]
  • [Cites] Nat Immunol. 2007 Dec;8(12):1313-23 [17982459.001]
  • [Cites] Cell Stem Cell. 2007 Dec 13;1(6):635-45 [18371405.001]
  • [Cites] Blood. 2008 May 1;111(9):4490-5 [18309032.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Curr Drug Targets. 2008 Oct;9(10):842-50 [18855618.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4193-201 [18716133.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3396-401 [19218430.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):445-50 [15725479.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1277-84 [10545994.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3633-43 [10572074.001]
  • [Cites] Science. 2000 Jun 16;288(5473):2051-4 [10856220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] J Exp Med. 2001 Apr 2;193(7):855-62 [11283158.001]
  • [Cites] Trends Cell Biol. 2001 Mar;11(3):130-5 [11306274.001]
  • [Cites] J Immunol. 2001 Sep 1;167(5):2547-54 [11509594.001]
  • [Cites] J Exp Med. 2001 Aug 20;194(4):541-9 [11514609.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 19;315(4):912-8 [14985099.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2555-64 [9326221.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [CommentIn] Cell. 2009 Jul 23;138(2):226-8 [19632173.001]
  • (PMID = 19632179.001).
  • [ISSN] 1097-4172
  • [Journal-full-title] Cell
  • [ISO-abbreviation] Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009302; United States / NIAID NIH HHS / AI / T32 AI007290; United States / NCI NIH HHS / CA / R01 CA086017-07; United States / NCI NIH HHS / CA / R01 CA086017-06; United States / NCI NIH HHS / CA / R01 CA086017; United States / NCI NIH HHS / CA / R01CA86017; United States / NCI NIH HHS / CA / R01 CA086017-08; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R01 CA086017-09; United States / NCI NIH HHS / CA / R01 CA086017-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD47; 0 / Ptpns1 protein, mouse; 0 / Receptors, Immunologic
  • [Other-IDs] NLM/ NIHMS122682; NLM/ PMC2726837
  •  go-up   go-down


2. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR: Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res; 2010 Mar 15;16(6):1865-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
  • PURPOSE: The Forkhead transcription factors (FOXO) are tumor suppressor genes regulating differentiation, metabolism, and apoptosis that functionally interact with signal transduction pathways shown to be deregulated and prognostic in acute myelogenous leukemia (AML).
  • EXPERIMENTAL DESIGN: We used reverse-phase protein array methods to measure the level of total and phosphoprotein expression of FOXO3A, in leukemia-enriched protein samples from 511 newly diagnosed AML patients.
  • Levels of total FOXO3A were higher at relapse compared with diagnosis.
  • [MeSH-major] Forkhead Transcription Factors / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Promyelocytic, Acute / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis. Protein Array Analysis. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Mol Med. 2008 May;14(5):219-27 [18403263.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Eur J Haematol. 2008 Aug;81(2):83-93 [18363870.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(19):5886-98 [18644865.001]
  • [Cites] Blood. 2009 Jan 1;113(1):154-64 [18840713.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3829-39 [19066462.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):752-7 [19188143.001]
  • [Cites] Bioinformatics. 2009 Jun 1;25(11):1384-9 [19336447.001]
  • [Cites] Leuk Res. 2009 Dec;33(12):1706-9 [19457552.001]
  • [Cites] Cancer Invest. 2009 Jan;27(1):52-9 [19160093.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):952-65 [11154281.001]
  • [Cites] Biochem J. 2001 May 1;355(Pt 3):597-607 [11311120.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):81-91 [12150827.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5871-82 [12488318.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):416-8 [15149589.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] J Histochem Cytochem. 1996 Dec;44(12):1353-62 [8985127.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):195-202 [9010221.001]
  • [Cites] Genomics. 1998 Jan 15;47(2):187-99 [9479491.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] BMC Neurosci. 2004 Nov 29;5:48 [15569384.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7410-25 [16288288.001]
  • [Cites] Cell. 2006 Jun 2;125(5):987-1001 [16751106.001]
  • [Cites] Exp Gerontol. 2006 Aug;41(8):709-17 [16806782.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Science. 2006 Oct 13;314(5797):294-7 [17038621.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):534-47 [16888645.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1949-58 [17900262.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]
  • [Cites] Nucleic Acids Res. 2007;35(20):6984-94 [17940099.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):101-12 [18371339.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2276-88 [18391970.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2351-63 [18391977.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jul;12(7):905-16 [18554157.001]
  • (PMID = 20215543.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108631
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS378348; NLM/ PMC3385949
  •  go-up   go-down


3. Yan WH, Lin A, Chen BG, Luo WD, Dai MZ, Chen XJ, Xu HH, Li BL: Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med; 2008 Jun;12(3):889-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.
  • In the current study, HLA-G expression was analysed in different types of patients: de novo acute myeloid leukaemia (AML, n = 54), B cell acute lymphoblastic leukaemia (B-ALL, n= 13), chronic myeloid leukaemia (CML, n= 9) and myelodysplastic syndrome (MDS, n= 11).
  • [MeSH-major] HLA Antigens / immunology. Histocompatibility Antigens Class I / immunology. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adult. B-Lymphocytes / immunology. Chromosome Banding. Cytotoxicity Tests, Immunologic. Female. Flow Cytometry. Fluorescein-5-isothiocyanate / metabolism. Fluorescent Dyes / metabolism. HLA-G Antigens. Humans. Immunophenotyping. Karyotyping. Killer Cells, Natural / immunology. L-Lactate Dehydrogenase / secretion. Male. Middle Aged. Prognosis. Retrospective Studies. T-Lymphocytes / immunology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18494931.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; EC 1.1.1.27 / L-Lactate Dehydrogenase; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC4401132
  •  go-up   go-down


Advertisement
4. Styczynski J, Gil L, Derwich K, Wachowiak J, Balwierz W, Badowska W, Krawczuk-Rybak M, Matysiak M, Wieczorek M, Balcerska A, Sonta-Jakimczyk D, Stefaniak J, Kowalczyk J, Urasinski T, Sobol G, Komarnicki M, Wysocki M: Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res; 2009 May;29(5):1643-50
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
  • The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • Cellular ex vivo drug resistance was tested by means of the MTT assay.
  • RESULTS: Clofarabine had comparable ex vivo activity against lymphoblasts and myeloblasts, both on initial diagnosis and at relapse, both in children and in adults.
  • Its activity in acute myeloid leukemia was independent of patient age.
  • CONCLUSION: In comparison to childhood acute lymphoblastic leukemia, lack of differences in ex vivo activity gives rationale for use of clofarabine in refractory and relapsed pediatric and adult patients with acute myeloid leukemia.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443380.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


5. Graf M, Reif S, Kröll T, Hecht K, Nuessler V, Schmetzer H: Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol; 2006 Apr;81(4):227-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.
  • There is evidence to suggest, that cellular adhesion molecules and receptors could play a role in leukemia, e.g., through altered adhesive qualities of leukemic blasts.
  • We have studied the expression of the beta2-integrin Mac-1 (CD11b) on mononuclear cells in 48 patients with AML at first diagnosis by flow cytometry using a direct fluorescein-conjugated antibody.
  • [MeSH-major] Antigens, CD11b / blood. Biomarkers, Tumor / blood. Blast Crisis / blood. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Endothelial Cells / metabolism. Endothelial Cells / pathology. Female. Humans. Macrophage-1 Antigen / blood. Male. Middle Aged. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16550517.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Biomarkers, Tumor; 0 / Macrophage-1 Antigen
  •  go-up   go-down


6. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Schmetzer H: High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Am J Hematol; 2005 May;79(1):26-35
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
  • CD87) is a membrane protein responsible for plasmin expression on cells facilitating cellular extravasations and tissue invasions.
  • We studied the expression of the UPA-R on bone marrow (BM) cells of 93 patients with acute myeloid leukemia at first diagnosis and 8 healthy probands as controls by FACS analysis using phycoerythrin (PE)-conjugated antibodies.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Aged. Antigens, CD / genetics. Bone Marrow Cells / immunology. Female. Flow Cytometry. Genetic Markers. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Urokinase Plasminogen Activator

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 15849776.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Genetic Markers; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator
  •  go-up   go-down


7. Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K, AML Study Group: The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica; 2005 Dec;90(12):1626-34
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
  • BACKGROUND AND OBJECTIVES: Translocation (9;11) is the most common t(11q23) in acute myeloid leukemia (AML).
  • Because of the relatively low sensitivity of the RQ-PCR (10(-3) to 10(-4) at the cellular level), samples from RQ-PCR-negative patients were also analyzed by nested polymerase chain reaction (nPCR; sensitivity 10-4 to 10-5 at the cellular level).
  • Quantitative MLL-AF9 levels at diagnosis or during and after therapy had no prognostic impact.
  • [MeSH-major] Biomarkers, Tumor / blood. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid / pathology. Myeloid-Lymphoid Leukemia Protein / blood. Oncogene Proteins, Fusion / blood. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Idarubicin / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Multicenter Studies as Topic. Neoplasm, Residual. Peripheral Blood Stem Cell Transplantation. Polymerase Chain Reaction / methods. Prognosis. Randomized Controlled Trials as Topic. Recurrence. Remission Induction. Survival Analysis. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Dec;90(12):1586A [16330423.001]
  • (PMID = 16330435.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; ICE protocol 4; MAC chemotherapy protocol
  •  go-up   go-down


8. Zhang JF, Miao KR, Qiu HR, Yang H, Wu YJ, Qiao C, Li JY: [Acute myeloid leukemia with the morphological characteristics of prolymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1211-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloid leukemia with the morphological characteristics of prolymphocytic leukemia].
  • To investigate the clinical, cellular morphology, immunophenotype, and cytogenetic characteristics of acute myeloid leukemia (AML) which are very similar to the morphological characteristics of prolymphocytic leukemia (PLL), the morphological features of bone marrow cells from patient were observed by light microscope, the immunophenotypes were detected by flow cytometry, the karyotypes were analyzed by conventional cytogenetic method, the hybridization signals were determined by fluorescence in situ hybridization.
  • The results indicated that the clinical features were in accordance with acute leukemia and the immunophenotyping results showed malignant cells originated from myeloid lineage, while the cytomorphology analysis showed that the blastic cells were more like the lymphoid lineage.
  • In conclusion, acute leukemia has high heterogenicity, which could be defined as AML, but more like lymphocytic origination by morphological study.
  • Immunophenotyping analysis could contribute to the final diagnosis of malignant cells.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928630.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Capria S, Gentile G, Capobianchi A, Cardarelli L, Gianfelici V, Trisolini SM, Foà R, Martino P, Meloni G: Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia. J Med Virol; 2010 Jul;82(7):1201-7
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
  • Little is known about the incidence and clinical impact of cytomegalovirus (CMV) infection in patients with acute myeloid leukemia at the time of diagnosis and during chemotherapy.
  • The aims of the present study were to assess prospectively the incidence of active CMV infection in 69 consecutive patients with acute myeloid leukemia and to describe the outcomes of treatment. pp65 antigenemia was monitored at diagnosis, post-induction and post-consolidation chemotherapy, and whenever CMV reactivation was suspected.
  • In conclusion, patients with acute myeloid leukemia receiving chemotherapy should be monitored for active CMV infection.
  • Controlled studies are needed to assess the relevance of pre-emptive anti-CMV therapy in patients with acute myeloid leukemia receiving chemotherapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytarabine / therapeutic use. Cytomegalovirus / isolation & purification. Cytomegalovirus Infections / drug therapy. Cytomegalovirus Infections / epidemiology. Leukemia, Myeloid, Acute / virology
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antibodies, Viral / blood. Antigens, Viral / blood. Antineoplastic Agents / therapeutic use. Daunorubicin / therapeutic use. Female. Humans. Hydroxyurea / therapeutic use. Incidence. Italy / epidemiology. Male. Middle Aged. Monitoring, Physiologic. Phosphoproteins / blood. Treatment Outcome. Viral Matrix Proteins / blood. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20513085.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Viral; 0 / Antigens, Viral; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Phosphoproteins; 0 / Viral Matrix Proteins; 0 / cytomegalovirus matrix protein 65kDa; 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Bogason A, Masquelier M, Lafolie P, Skogastierna C, Paul C, Gruber A, Vitols S: Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett; 2010 Dec;4(4):228-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
  • BACKGROUND: Anthracyclines like daunorubicin (DNR) are important drugs in the treatment of acute myeloid leukaemia (AML).
  • In vitro studies have shown that cellular metabolism of anthracyclines could play a role in drug resistance.
  • METHODS: Mononuclear blood cells from 25 AML patients were isolated at diagnosis and used in a metabolic assay to determine the % DOL formed. mRNA and western blot analysis were performed on the 2 most likely candidates for anthracycline metabolism; carbonyl reductase 1 (CR1) and aldoketoreductase 1A1 (AKR1A1).
  • Cellular DNR metabolism correlated significantly with CR1 protein expression, determined by western blot, (p < 0.05, R2 = 0,229) while no significant correlation was found with AKR1A1 protein expression.
  • [MeSH-major] Antibiotics, Antineoplastic / metabolism. Daunorubicin / metabolism. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Oxidoreductases / antagonists & inhibitors. Alcohol Oxidoreductases / genetics. Alcohol Oxidoreductases / metabolism. Biotransformation. Blotting, Western. Chromatography, High Pressure Liquid. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20670211.001).
  • [ISSN] 1874-0758
  • [Journal-full-title] Drug metabolism letters
  • [ISO-abbreviation] Drug Metab Lett
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Enzyme Inhibitors; 0 / RNA, Messenger; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.184 / CBR1 protein, human; YDU8YIP30L / daunorubicinol; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


11. Abdel Alim A, Youssef SR, Farouk HM: The prognostic potential of bone marrow cyclin E and P27, in Egyptian patients with acute myeloid leukemia. Egypt J Immunol; 2010;17(1):9-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic potential of bone marrow cyclin E and P27, in Egyptian patients with acute myeloid leukemia.
  • There are few molecular biologic determinants that may be prognostic for patients with acute myeloid leukemia (AML).
  • To investigate the importance of cell cycle defects in AML, the cellular levels of cyclin E and the cyclin-dependent kinase inhibitor P27 (Kip 1) were evaluated in thirty AML patients (11 males and 19 females) diagnosed by standard clinical, morphological and immunophenotypic criteria and staged according to the FAB classification.
  • Cyclin E was high among M4/M5 cases and low among M3 cases and showed a statistically significant positive correlation with percentage of blast cells, aberrant phenotype and abnormal karyotype at diagnosis.
  • P27 showed a statistically significant negative correlation to the percentage of blasts at diagnosis and a significant positive correlation with achievement of CR.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22053605.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


12. El-Naggar AA, Mahmoud BF, Abou Shamaa LA, Salama MA: Changes of serum growth factors (IGF-I & IGFBP-2) and prediction of response to chemotherapy in patients with acute myeloid leukemia. Egypt J Immunol; 2008;15(2):73-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of serum growth factors (IGF-I & IGFBP-2) and prediction of response to chemotherapy in patients with acute myeloid leukemia.
  • Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) possess mitogenic properties promoting cellular proliferation and inhibiting cellular apoptosis.
  • In the present study, we investigated IGF-I and IGFBP-2 in patients with acute myeloid leukemia (AML) for their predictive value to identify patients who could be responsive to conventional induction chemotherapy.
  • However, IGFBP-2 was significantly lower in Responders than in Non-Responders both at diagnosis (4250 +/- 155.099 pg/ml vs 6866.67 +/- 352.122 pg/ml, respectively) as well as after induction cycle of chemotherapy (4130 +/- 324.225 pg/ml vs 7150.00 +/- 265.290 pg/ml, respectively).
  • It is concluded that, serum IGFBP-2 is considered as an independent factor that adds additional information for the prediction of relapse or treatment failure and patients with concentration > or = 4900 pg/ml at diagnosis are suspected to be nonresponders to conventional induction chemotherapy.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306690.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 04079A1RDZ / Cytarabine; 67763-96-6 / Insulin-Like Growth Factor I; 80168379AG / Doxorubicin
  •  go-up   go-down


13. Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, Ruan G, Liu Y, Chen S, Huang X: Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res; 2009 Mar;33(3):384-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
  • Both WT1 and PRAME are highly expressed in acute myeloid leukemia (AML) patients.
  • The exception was that one patient's WT1 significantly decreased at relapse compared to diagnosis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasm, Residual / diagnosis. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Case-Control Studies. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 May;33(5):603-4 [19269525.001]
  • (PMID = 18950857.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human; 0 / WT1 Proteins
  •  go-up   go-down


14. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Maciejka-Kapuscinska L: Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol; 2007 Nov;133(11):875-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
  • PURPOSE: Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins.
  • (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia.
  • CONCLUSIONS: The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local / diagnosis. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2007 Nov;133(11):895. Wachowiak, Jacek [added]; Konatkowska, Benigna [added]; Gil, Lidia [added]; Balcerska, Anna [added]; Maciejka-Kapuscinska, Lucyna [added]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):379-86 [11984797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3120-6 [11595704.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):45-9 [10695821.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3352-60 [12384437.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4493-8 [12816874.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):264-79 [15491285.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):963-4 [14990658.001]
  • [Cites] Pediatr Int. 1999 Dec;41(6):641-7 [10618884.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2023-30 [10602424.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):195-9 [14752887.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 1999 Nov;38(11):760-3 [11798719.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1843-8 [12685842.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1083-6 [12631611.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):876-82 [10554796.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leuk Lymphoma. 1994 Apr;13(3-4):187-201 [8049644.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2117-24 [16107894.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Curr Opin Oncol. 1995 Jan;7(1):36-44 [7696362.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Sep;4(5):705-13 [15347263.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):19-27 [12844332.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Mar;41(3):183-5 [11940320.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8661-8 [16361551.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):599-604 [10404077.001]
  • [Cites] Sao Paulo Med J. 2004 Jul 1;122(4):166-71 [15543372.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):875-9 [12153178.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Ai Zheng. 2005 Aug;24(8):1015-7 [16086885.001]
  • [Cites] Exp Hematol. 1998 Nov;26(12):1111-7 [9808049.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2063-71 [16107896.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):321-7 [10050715.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1302-8 [12423683.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 17671794.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


15. Cocco L, Manzoli L, Palka G, Martelli AM: Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia. Adv Enzyme Regul; 2005;45:126-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia.
  • Moreover, non-specific alterations in chromosome 20 have been found in patients affected by MDS and acute myeloid leukemia AML.
  • MDS is an adult hematological disease that evolves into AML in about 30% of the cases.
  • The MDS patients, bearing the deletion, rapidly evolved to AML, whilst the normal karyotype MDS patients, showing non-deletion of PLC beta1 gene, are still alive at least 24 months after the diagnosis.
  • [MeSH-major] Cell Cycle / physiology. Cell Nucleus / enzymology. Isoenzymes / physiology. Leukemia, Myeloid / pathology. Myelodysplastic Syndromes / pathology. Type C Phospholipases / physiology
  • [MeSH-minor] Acute Disease. Gene Deletion. Humans. Phospholipase C beta. Signal Transduction / physiology


16. Parovichnikova EN, Gal'tseva IV, Vorob'ev IA, Savchenko VG: [Characteristics of T-cell immunity in patients with acute leukemia]. Ter Arkh; 2006;78(7):18-25
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of T-cell immunity in patients with acute leukemia].
  • AIM: To study a cytokine profile of cytotoxic T-cells and T-helpers at diagnosis of acute myeloid and lymphoblastic leukemia (AML and ALL) and at different stages of its treatment.
  • MATERIAL AND METHODS: T-cell population of peripheral blood lymphocytes was studied in 19 AML patients at diagnosis, 13 AML patients in remission, 5 AML patients in developing recurrence and 5 ALL patients at diagnosis.
  • The percentage of CD3+CD8- cells (T-helpers) producing IF-g was similar in the patients at diagnosis and in complete remission being higher than in healthy donors.
  • CONCLUSION: The results obtained evidence for different polarization of T-cell immunity in AML and ALL patients at the time of diagnosis, remission and recurrence: in the onset of AML there was an increase in the production of Th1--proinflammatory cytokines, in ALL--in percent of Th-2 cytokines.
  • [MeSH-major] Leukemia / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antigens, CD / biosynthesis. Antigens, CD / immunology. Cytokines / biosynthesis. Cytokines / immunology. Female. Flow Cytometry. Humans. Immunity, Cellular. Male. Middle Aged. Th1 Cells / immunology. Th1 Cells / metabolism. Th2 Cells / immunology. Th2 Cells / metabolism

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944746.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines
  •  go-up   go-down


17. Styczynski J: Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol; 2007 Apr;8(2):59-75
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug resistance in childhood acute myeloid leukemia.
  • Different problems of drug resistance in childhood AML, with emphasis to age and in comparison to adult AML are presented.
  • In vitro and in vivo aspects are discussed, together with mechanisms of resistance to cytostatic drugs, focused on clinical relevance of cellular drug resistance profile and its prognostic value.
  • Cellular drug resistance in AML cells seems to be similar throughout all other age groups, however the higher the age, the worse the outcome.
  • In childhood AML, no drug is more effective in comparison to ALL, and cellular drug resistance is partially related to chromosomal abnormalities.
  • Pediatric AML is equally resistant as adult AML.
  • Pediatric and adult AML, respectively, are possibly equally drug resistant on initial diagnosis and at relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430154.001).
  • [ISSN] 1873-4316
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 165
  •  go-up   go-down


18. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J: Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol; 2008 Sep;88(2):209-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
  • It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53).
  • CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients.
  • Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70).
  • In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Male. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 Nov;89(11):1399-401 [15531467.001]
  • [Cites] Leukemia. 2003 Feb;17 (2):468-70 [12592351.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] Blood. 1986 Apr;67(4):1048-53 [2937468.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):344-5 [17897313.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1003-7 [16038726.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):687-8 [12899727.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1557-8 [15229619.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1501-7 [9305605.001]
  • (PMID = 18668307.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


19. Mao P, Luo CR, Zhang YP, Wang CX, Xu YL, Ying Y, DU QH, Xie JJ: [Expression and clonal proliferation of TCR Vbeta subfamilies of peripheral T-cells in acute myeloid leukemia patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):431-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clonal proliferation of TCR Vbeta subfamilies of peripheral T-cells in acute myeloid leukemia patients].
  • This study was purposed to investigate the expression and clonal proliferation of receptor (TCR) Vbeta subfamilies of the T-cells in acute leukemic patients at different disease status (onset, complete remission or relapse) and to analyze the influence of the leukemic cell load on anti-leukemic effect of peripheral T-lymphocytes of the patients.
  • The application, clonal proliferation, cellular complexity of T-cells, and the variation of immunotypes of T-cells were compared.
  • Only 1 - 2 clonal proliferation of TCR Vbeta subfamilies existed in 9 out of 11 patients at initial diagnosis which increased at remission.
  • There was an obvious decrease of CDR3 complexity at initial diagnosis or relapse, while CDR3 complexity would be partially improved at remission.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379582.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


20. de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES: Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res; 2008 Feb 1;14(3):924-30
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
  • PURPOSE: We hypothesized that downstream effects of endogenous vascular endothelial growth factor (VEGF)/VEGF receptor signaling on acute myelogenous leukemia (AML) cell survival resulted in increased in vitro cellular drug resistance and a longer time to kill most leukemic cells in vivo upon drug exposure.
  • EXPERIMENTAL DESIGN: In primary AML cells from pediatric patients, VEGFA and VEGFC mRNA expression and in vitro cellular resistance to nine cytotoxic drugs were studied.
  • As in vivo equivalents for in vitro drug resistance, in vivo AML blast reduction upon drug exposure, measured as blast cell reduction on day 15 in the bone marrow and as time in days from diagnosis to complete remission (CR) were used.
  • Time to reach CR was studied using linear regression analysis with VEGFC, age at diagnosis, sex, treatment protocol, FAB type, cytogenetic risk profile, and WBC counts as variables.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Vascular Endothelial Growth Factor C / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Karyotyping. Male. RNA, Messenger / genetics. Risk Assessment. Treatment Outcome. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245556.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


21. Raponi S, De Propris MS, Wai H, Intoppa S, Elia L, Diverio D, Vitale A, Foà R, Guarini A: An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. Haematologica; 2009 Dec;94(12):1767-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.
  • Tyrosine kinase inhibitors have profoundly modified the treatment and prognosis of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia.
  • A rapid and accurate detection of the BCR-ABL fusion protein is paramount today for an optimal management of Ph(+) acute lymphoblastic leukemia.
  • The assay was applied to 101 primary patient samples (94 acute leukemias and 7 chronic myeloid leukemia blast crisis) and the results of the immunoassay were concordant with those obtained by conventional molecular techniques.
  • This flow cytometric immunoassay has important implications for perfecting the management of Ph(+) acute lymphoblastic leukemia patients worldwide.
  • [MeSH-major] Flow Cytometry / methods. Fusion Proteins, bcr-abl / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunoassay / instrumentation. Immunoassay / methods. Infant. Male. Middle Aged. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Oct;36(1):49-58 [10996522.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Haematologica. 2003 Mar;88(3):275-9 [12651265.001]
  • [Cites] Nature. 1982 Dec 23;300(5894):765-7 [6960256.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Mayo Clin Proc. 2005 Nov;80(11):1517-27 [16295033.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):652-9 [16988590.001]
  • [Cites] Blood. 2007 May 1;109(9):3676-8 [17213285.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Blood. 2007 May 15;109(10):4143-50 [17264298.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Apr;5(4):270-2, 292 [17607286.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4808-17 [19064740.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1106-17 [19387467.001]
  • [CommentIn] Haematologica. 2009 Dec;94(12):1639-41 [19996114.001]
  • (PMID = 19608682.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2791932
  •  go-up   go-down


22. Maha A, Cheong SK, Leong CF, Seow HF: Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy. Malays J Pathol; 2009 Dec;31(2):81-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
  • We examined the expression pattern of proinflammatory cytokines, signaling molecules of the PI3K and MAPK pathways molecules and death receptor, DR5 on paired samples at diagnosis and during chemotherapy in acute myeloid leukaemia patients treated with cytosine arabinoside and daunorubicin.
  • IL-beta and IL-18 were also found to be higher in chemo-resistant cases at diagnosis and during chemotherapy.
  • Thus, expression of various cellular molecules in leukaemic blasts during chemotherapy may be useful in predicting treatment outcome.
  • These cellular molecules may also be potential targets for alternative therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Leukemia, Myeloid, Acute / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cytarabine / administration & dosage. Cytokines / drug effects. Cytokines / genetics. Cytokines / metabolism. Daunorubicin / administration & dosage. Elafin / drug effects. Elafin / genetics. Elafin / metabolism. Female. Humans. Male. Middle Aged. Mitogen-Activated Protein Kinases / drug effects. Mitogen-Activated Protein Kinases / genetics. Mitogen-Activated Protein Kinases / metabolism. Prognosis. RNA, Messenger / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / drug effects. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Remission Induction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514850.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Elafin; 0 / PI3 protein, human; 0 / RNA, Messenger; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 04079A1RDZ / Cytarabine; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


23. Galm O, Wilop S, Lüders C, Jost E, Gehbauer G, Herman JG, Osieka R: Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol; 2005 Dec;84 Suppl 1:39-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.
  • The methylation status of the promoter-associated CpG islands from 11 well-characterized cancer-related genes was analyzed by methylation-specific polymerase chain reaction in 60 adult patients with acute myelogenous leukemia (AML) at diagnosis.
  • Our data indicate that hypermethylation of multiple genes involving fundamental cellular pathways is a common event in AML, which varies greatly in frequency among the genes examined.
  • [MeSH-major] CpG Islands / genetics. DNA Methylation. Epigenesis, Genetic. Genes, Neoplasm / genetics. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Gene Silencing. Humans. Karyotyping. Male. Middle Aged. Prognosis. Risk Factors


24. Jun KR, Jang S, Chi HS, Lee KH, Lee JH, Choi SJ, Seo JJ, Moon HN, Im HJ, Park CJ: Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia. Korean J Lab Med; 2007 Apr;27(2):89-95
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
  • BACKGROUND: Cellular drug resistance is supposed to play a major role in chemotherapy failure or relapse.
  • METHODS: For MTT assay, we obtained bone marrow aspirates from 103 patients with acute leukemia at the time of initial diagnosis or relapse.
  • CONCLUSIONS: Although it does not provide the insight into the mechanisms that cause drug resistance, the MTT assay may be a useful tool in individually optimizing the chemotherapy of patients with acute leukemia.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Child. Child, Preschool. Coloring Agents. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Drug Evaluation, Preclinical. Drug Resistance, Neoplasm. Female. Humans. Infant. Male. Middle Aged. Tetrazolium Salts. Thiazoles. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094557.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Coloring Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 04079A1RDZ / Cytarabine; 298-93-1 / thiazolyl blue; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


25. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • Of the malignant cases, there was a higher proportion of correct diagnosis based on morphology in the acute malignancies (67%) versus the chronic malignancies (47%).
  • Features most useful for diagnosis of malignancy included cellular monotony and nuclear contour irregularity.
  • The diagnosis of malignancy based on morphology alone is difficult in CSF.
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytological Techniques. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A: Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res; 2010 Jul 15;16(14):3721-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
  • PURPOSE: Complete response to induction chemotherapy is observed in approximately 60% of patients with newly diagnosed non-M3 acute myelogenous leukemia (AML).
  • Results were independent of cytogenetics, FLT3 mutational status, and diagnosis of secondary AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Cohort Studies. Female. Flow Cytometry. Humans. Male. Middle Aged. Mutation. Predictive Value of Tests. Prospective Studies. Reproducibility of Results. Signal Transduction / drug effects. Single-Cell Analysis. Young Adult. fms-Like Tyrosine Kinase 3 / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Blood. 1998 Feb 15;91(4):1101-34 [9454740.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):596-604 [20026798.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Cytokines Cell Mol Ther. 1998 Sep;4(3):187-98 [9825844.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Crit Care. 2004 Dec;8(6):508-12 [15566624.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):68-75 [15604894.001]
  • [Cites] Science. 2005 Apr 22;308(5721):523-9 [15845847.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):195-221 [16236521.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):146-55 [16491074.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Nat Methods. 2006 May;3(5):361-8 [16628206.001]
  • [Cites] Leukemia. 2006 Jun;20(6):965-70 [16598313.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):438-49 [16965385.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Front Biosci. 2007;12:800-15 [17127321.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1903-12 [18042804.001]
  • [Cites] Leuk Res. 2008 Jun;32(6):913-8 [17928050.001]
  • [Cites] Leuk Res. 2008 Jun;32(6):944-53 [18206229.001]
  • [Cites] Blood. 2008 May 1;111(9):4490-5 [18309032.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7358-67 [18490735.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] Front Biosci. 2008;13:4605-16 [18508532.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jan 1;113(1):28-36 [18827183.001]
  • [Cites] Blood. 2009 Jan 1;113(1):154-64 [18840713.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3088-91 [19171880.001]
  • [Cites] Br J Haematol. 2009 Jun;145(5):555-68 [19344393.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3198-204 [19451432.001]
  • [Cites] Hematology. 2009 Aug;14(4):204-12 [19635183.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Nat Immunol. 2002 Dec;3(12):1129-34 [12447370.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11 [12447846.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Feb 1;101(3):837-45 [12393383.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Cell. 2004 Jul 23;118(2):217-28 [15260991.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • (PMID = 20525753.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108631
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ NIHMS378349; NLM/ PMC3385931
  •  go-up   go-down


27. Kuliszkiewicz-Janus M, Tuz MA, Kiełbiński M, Jaźwiec B, Niedoba J, Baczyński S: 31P MRS analysis of the phospholipid composition of the peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) of patients with acute leukemia (AL). Cell Mol Biol Lett; 2009;14(1):35-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 31P MRS analysis of the phospholipid composition of the peripheral blood mononuclear cells (PBMC) and bone marrow mononuclear cells (BMMC) of patients with acute leukemia (AL).
  • The aim of this study was to evaluate the phospholipid concentration in acute leukemia (AL) blast cells from peripheral blood (PBMC) and bone marrow (BMMC).
  • This investigation was carried out on phospholipid extracts from PBMC and BMMC from 15 healthy volunteers and 77 patients with AL (samples taken at the moment of diagnosis).
  • [MeSH-major] Bone Marrow Cells / chemistry. Leukemia, Myeloid, Acute / blood. Leukocytes, Mononuclear / chemistry. Phospholipids / analysis
  • [MeSH-minor] Adult. Cell Extracts. Diphosphonates. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839072.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cell Extracts; 0 / Diphosphonates; 0 / Phospholipids
  •  go-up   go-down


28. Gooneratne LV, Wijeratne MD, Gunasekara HD, Tudawe MN: Acute leukaemia of ambiguous lineage--a diagnostic dilemma. Ceylon Med J; 2009 Jun;54(2):51-3
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia of ambiguous lineage--a diagnostic dilemma.
  • Acute leukaemia of ambiguous lineage (ALAL) is a rare form of leukaemia in which morphologic, cytochemical and immuno-phenotypic features of the proliferating blasts lack sufficient evidence to classify them as myeloid or lymphoid in origin or have characteristics of both myeloid and lymphoid cells.
  • We report a 22-year-old man presenting with clinical features of an acute lymphoblastic leukaemia but blasts in his blood and bone marrow with morphological features of myeloblasts.
  • His immuno-phenotyping by flowcytometry showed antigens specific for both myeloid and B-lymphoid lineages.
  • We highlight the importance of correlating clinical features with cellular morphology when diagnosing acute leukaemias, especially when facilities for flowcytometry are not routinely available.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670549.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


29. Gerr HD, Nassin ML, Davis EM, Jayathilaka N, Neilly ME, Schlegelberger B, Zhang Y, Rowley JD: Cytogenetic and molecular study of the PRDX4 gene in a t(X;18)(p22;q23): a cautionary tale. Cancer Genet Cytogenet; 2007 Jul 15;176(2):131-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genes within this family exhibit thioredoxin-dependent peroxidase activity and have been implicated in cellular functioning, including proliferation and differentiation.
  • Recently, PRDX4 has been identified as a partner gene in a t(X;21) translocation in a patient with acute myeloid leukemia.
  • To determine whether PRDX4 was involved in other translocations, leukemia cells from 15 patients with Xp22 abnormalities were screened for involvement of the gene using fluorescence in situ hybridization (FISH).
  • One sample from a 41-year-old woman with acute lymphoblastic leukemia showed three signals when hybridized with the PRDX4 probe.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Jun;14(6):1031-8 [10865969.001]
  • [Cites] Antioxid Redox Signal. 2005 May-Jun;7(5-6):768-77 [15890023.001]
  • [Cites] Trends Biochem Sci. 2003 Jan;28(1):32-40 [12517450.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):396-405 [12800151.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):305-12 [14719106.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):365-70 [15188461.001]
  • [Cites] Ann Hematol. 1995 Apr;70(4):195-201 [7748964.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):30952-61 [9388242.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):255-62 [9439652.001]
  • [Cites] Leukemia. 1998 May;12(5):779-87 [9593281.001]
  • [Cites] Annu Rev Genet. 1998;32:495-519 [9928489.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2038-42 [10068677.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Leukemia. 2005 Apr;19(4):557-63 [15744345.001]
  • [Cites] Antioxid Redox Signal. 2000 Fall;2(3):507-18 [11229364.001]
  • (PMID = 17656256.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084405; United States / NCI NIH HHS / CA / CA84405; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R01 CA084405-05; United States / NCI NIH HHS / CA / CA084405-05
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; EC 1.11.1.15 / PRDX4 protein, human; EC 1.11.1.15 / Peroxiredoxins
  • [Other-IDs] NLM/ NIHMS28393; NLM/ PMC2083648
  •  go-up   go-down


30. Tsirigotis PD, Resnick IB, Or R, Elad S, Zilberman I, Yoffe L, Levovic A, Miron S, Gesundheit B, Slavin S, Shapira MY: Post-hematopoietic stem cell transplantion immune-mediated cytopenias. Immunotherapy; 2009 Jan;1(1):39-47
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exact pathogenesis of immune pancytopenia is not well known although it is possible that cellular immunity may play a significant role.
  • Differential diagnosis from other causes of post-transplant pancytopenia is of extreme value because these disorders can respond to various treatment modalities.
  • [MeSH-major] Bone Marrow / pathology. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / therapy. Postoperative Complications. Transplantation Conditioning
  • [MeSH-minor] Adult. Aged. Chimerism. Cyclosporine / therapeutic use. Female. Hematopoietic Stem Cell Mobilization. Histocompatibility. Humans. Immunoglobulins, Intravenous / therapeutic use. Male. Middle Aged. Myelodysplastic Syndromes. Neutropenia. Red-Cell Aplasia, Pure. Remission Induction. Thrombocytopenia

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20635972.001).
  • [ISSN] 1750-7448
  • [Journal-full-title] Immunotherapy
  • [ISO-abbreviation] Immunotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


31. Breccia M, Mengarelli A, Mancini M, Biondo F, Gentilini F, Latagliata R, Mandelli F, Alimena G: Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res; 2005 Jul;29(7):749-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk of transformation to acute leukaemia.
  • The median age at diagnosis was 43 years (range 21-50).
  • At a median follow-up of 15 months 19 patients (31%) progressed to acute myeloid leukaemia (AML).
  • [MeSH-minor] Adult. Anemia / etiology. Anemia, Sideroblastic / etiology. Cell Transformation, Neoplastic. Female. Humans. Leukemia / etiology. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis


32. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M: Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica; 2009 Feb;94(2):249-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Matched controls (N=31) were seronegative for viral hepatitides and were paired according to age, diagnosis, disease stage, conditioning regimen and donor type.
  • RESULTS: The median age of the seropositive patients was 49 (range 26-72); 15 had acute myeloid leukemia/myelodysplastic syndrome, 6 had chronic myeloid leukemia/myeloproliferative disease, 6 non-Hodgkin's lymphoma, 2 myeloma, 1 acute lymphocytic leukemia and 1 Hodgkin's lymphoma; 61% had poor risk disease; 68% had related donors; 68% received reduced intensity conditioning; 7 patients had mildly abnormal alanine transaminase levels (all less than three times the upper limit of normal) and 1 patient had minimally elevated bilirubin.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Hematologic Neoplasms / complications. Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Humans. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):167-9 [8816147.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1127-36 [9949154.001]
  • [Cites] Hepatology. 1999 Mar;29(3):908-14 [10051497.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1893-9 [10347135.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1347-54 [15618844.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Hepatology. 2007 Sep;46(3):640-8 [17879366.001]
  • [Cites] J Hepatol. 2008 Jun;48(6):1008-17 [18433917.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1326-31 [9242569.001]
  • [Cites] Blood. 1999 May 15;93(10):3259-66 [10233877.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1486-91 [10589944.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(6):649-55 [11035372.001]
  • [Cites] Semin Liver Dis. 2002 Feb;22(1):27-42 [11928077.001]
  • [Cites] Curr Opin Investig Drugs. 2002 May;3(5):680-3 [12090539.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(4):295-300 [12621466.001]
  • [Cites] Antivir Chem Chemother. 2003 May;14(3):145-52 [14521331.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1618-24 [14576071.001]
  • [Cites] Bone Marrow Transplant. 2004 Jun;33(12):1181-5 [15094751.001]
  • [Cites] Blood. 2004 Aug 1;104(3):857-64 [15073038.001]
  • [Cites] Biometrics. 1978 Dec;34(4):541-54 [373811.001]
  • [Cites] Transplantation. 1987 Dec;44(6):778-83 [3321587.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] Bone Marrow Transplant. 1993 Feb;11(2):119-23 [7679597.001]
  • [Cites] Transplantation. 1994 Feb;57(3):393-7 [7509088.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1998-2004 [7511444.001]
  • [Cites] Bone Marrow Transplant. 1994 Apr;13(4):417-22 [8019465.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1349-50 [8049452.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):833-7 [7534164.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1614-8 [7632971.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):615-20 [7677303.001]
  • [Cites] Bone Marrow Transplant. 1995 Sep;16(3):407-11 [8535314.001]
  • [Cites] Bone Marrow Transplant. 1996 Jan;17(1):75-80 [8673059.001]
  • [CommentIn] Haematologica. 2009 Feb;94(2):170-2 [19181791.001]
  • (PMID = 19144658.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2635398
  •  go-up   go-down






Advertisement